A5 – Complexities with Polypharmacy

There are a number of challenges and difficulties for those working in medical information and pharmacovigilance functions regarding the emergence of new drugs and an increasing prevalence of polypharmacy. This session will look at common mechanisms underlying drug-drug and drug-herb interactions, emerging drug-drug interaction information, cumulative effects of medicationsand examine the role of the medical information and pharmacovigilance function within this setting. The session will also discuss the practicalities of collecting high level pharmacovigilance data.

Chairperson: Eoin Scannell, Fresenius Kabi